Detalhe da pesquisa
1.
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Lancet Oncol
; 20(12): 1670-1680, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31601496